Resectable pancreatic head cancer
Conditions
Brief summary
Overall survival at 18 months after the date of randomisation
Detailed description
Progression-free survival assessed at both 18 months and as time since randomisation,, Overall mortality at 1 year after commencement of allocated treatment for patients who ultimately underwent resection, Overall survival in both the intention-to-treat (ITT) and per-protocol populations, Overall survival and overall survival following resection, Histopathological response (R0 resection and [y]pN0 disease), Compliication rates at 90 days after surgery, Feasibility of neoadjuvant and adjuvant chemotherapy (as assessed by adverse events, dose reductions, and dose delays),, Completion rates of all parts of multimodal treatment, Health economics, Quality of life
Interventions
DRUGFLUOROURACIL
DRUGGEMCITABINE
DRUGIRINOTECAN
DRUGCAPECITABINE
DRUGOXALIPLATIN
DRUGCALCIUM FOLINATE
Sponsors
Oslo University Hospital HF
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival at 18 months after the date of randomisation | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival assessed at both 18 months and as time since randomisation,, Overall mortality at 1 year after commencement of allocated treatment for patients who ultimately underwent resection, Overall survival in both the intention-to-treat (ITT) and per-protocol populations, Overall survival and overall survival following resection, Histopathological response (R0 resection and [y]pN0 disease), Compliication rates at 90 days after surgery, Feasibility of neoadjuvant and adjuvant chemotherapy (as assessed by adverse events, dose reductions, and dose delays),, Completion rates of all parts of multimodal treatment, Health economics, Quality of life | — |
Countries
Norway, Sweden
Outcome results
None listed